📣 VC round data is live. Check it out!

electroCore Valuation Multiples

Discover revenue and EBITDA valuation multiples for electroCore and similar public comparables like Sequana Medical, Svas Biosana, Envoy Medical, Anatolia Geneworks and more.

electroCore Overview

About electroCore

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.


Founded

2005

HQ

United States

Employees

73

Financials (LTM)

Revenue: $36M
EBITDA: ($8M)

EV

$56M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

electroCore Financials

electroCore reported last 12-month revenue of $36M and negative EBITDA of ($8M).

In the same LTM period, electroCore generated $31M in gross profit, ($8M) in EBITDA losses, and had net loss of ($14M).

Revenue (LTM)


electroCore P&L

In the most recent fiscal year, electroCore reported revenue of $32M and EBITDA of ($9M).

electroCore is unprofitable as of last fiscal year, with gross margin of 87%, EBITDA margin of (27%), and net margin of (44%).

See analyst estimates for electroCore
LTMLast FY202320242025202620272028
Revenue$36M$32M$16M$25M$32M
Gross Profit$31M$28M$13M$21M$28M
Gross Margin87%87%83%85%87%
EBITDA($8M)($9M)($18M)($11M)($12M)
EBITDA Margin(21%)(27%)(114%)(43%)(37%)
EBIT Margin(36%)(41%)(120%)(48%)(41%)
Net Profit($14M)($14M)($19M)($12M)($14M)
Net Margin(38%)(44%)(117%)(47%)(44%)

Financial data powered by Morningstar, Inc.

electroCore Stock Performance

electroCore has current market cap of $55M, and enterprise value of $56M.

Market Cap Evolution


electroCore's stock price is $6.67.

electroCore share price increased by 0.6% in the last 30 days, and by 33.4% in the last year.

electroCore has an EPS (earnings per share) of $-1.68.

See more trading valuation data for electroCore
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$56M$55M0.0%0.6%-12.0%33.4%$-1.68

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

electroCore Valuation Multiples

electroCore trades at 1.6x EV/Revenue multiple, and (7.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for electroCore

EV / Revenue (LTM)


electroCore Financial Valuation Multiples

As of May 26, 2026, electroCore has market cap of $55M and EV of $56M.

electroCore has a P/E ratio of (4.0x).

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.7x3.5x2.2x1.7x
EV/EBITDA(7.4x)(6.4x)(3.1x)(5.1x)(4.8x)
EV/EBIT(4.3x)(4.3x)(2.9x)(4.6x)(4.3x)
EV/Gross Profit1.8x2.0x4.2x2.6x2.0x
P/E(4.0x)(4.0x)(2.9x)(4.7x)(4.0x)
EV/FCF—(6.8x)(3.8x)(8.1x)(6.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified electroCore Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

electroCore Margins & Growth Rates

electroCore grew revenue by 31% but EBITDA decreased by 33% in the last fiscal year.

In the most recent fiscal year, electroCore reported gross margin of 87%, EBITDA margin of (27%), and net margin of (44%).

See estimated margins and future growth rates for electroCore

electroCore Margins

Last FY202420252026202720282029
Gross Margin87%85%87%86%
EBITDA Margin(27%)(43%)(37%)(14%)
EBIT Margin(41%)(48%)(41%)(31%)
Net Margin(44%)(47%)(44%)(32%)
FCF Margin(26%)(28%)(26%)—

electroCore Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth31%57%27%31%
Gross Profit Growth30%62%30%30%
EBITDA Growth(33%)(40%)7%(50%)
EBIT Growth(1%)(37%)8%(1%)
Net Profit Growth(3%)(37%)17%(3%)
FCF Growth—(53%)19%—

Data powered by FactSet, Inc. and Morningstar, Inc.

electroCore Operational KPIs

electroCore's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.6M for the same period.

electroCore's Rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

electroCore's Rule of X is 63% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for electroCore
LTMLast FY202320242025202620272028
Rule of 409%17%———
Bessemer Rule of X54%63%———
Revenue per Employee—$0.4M———
Opex per Employee—$0.6M———
R&D Expenses to Revenue8%9%33%9%9%
Opex to Revenue—128%203%133%128%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

electroCore Competitors

electroCore competitors include Sequana Medical, Svas Biosana, Envoy Medical, Anatolia Geneworks, Sensus Healthcare, Modulight, K Pharma, Cleo Diagnostics, Bactiguard and Baird Medical Investment.

Most electroCore public comparables operate across Medical Devices, Diagnostics & Genomics, BioTech, DeepTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sequana Medical775.8x30.1x(2.0x)(4.0x)
Svas Biosana0.9x0.7x6.0x5.6x
Envoy Medical125.1x134.2x(1.4x)—
Anatolia Geneworks3.8x—(28.3x)—
Sensus Healthcare1.3x1.3x(3.6x)(3.4x)
Modulight5.4x5.1x(961.2x)79.7x
K Pharma——(7.3x)—
Cleo Diagnostics————

This data is available for Pro users. Sign up to see all electroCore competitors and their valuation data.

Start Free Trial

electroCore Funding History

Before going public, electroCore raised $125M in total equity funding, across 3 rounds.


electroCore Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-17Series BAmerican Investment Holdings; Knoll Capital Management; Merck Global Health Innovation Fund; The Vinik Family Foundation$34M—electroCore is a bioelectronic technology company developing non-invasive vagus nerve stimulation (nVNS) therapies, primarily gammaCore for headache disorders like migraine and cluster headache, with later expansions to wellness products like Truvaga and TAC-STIM. The company has relied heavily on government customers, with U.S. Department of Veterans Affairs generating significant revenue portions in later years (71.2% in 2025, 60.1% in 2023). gammaCore received FDA clearance in January 2018 for acute pain treatment associated with episodic cluster headache.
Sep-17Series B—$36M—electroCore, a U.S.-based bioelectronic medicine company, develops non-invasive vagus nerve stimulation (nVNS) therapies, including its gammaCore device for headache treatment and other neuromodulation applications. The company completed a $70 million Series B funding round announced on November 29, 2017, led by investors including Core Ventures, Merck Global Health Innovation Fund, Jeff Vinik’s group, and Knoll Capital, with assistance from Paulson Investment Company. This brought total funding raised to over $150 million, including a $32 million seed round and $55 million Series A led by Merck GHI and Core Ventures. Proceeds were allocated for commercial launch and expansion of gammaCore into the primary headache market, as well as continued clinical and scientific development of nVNS therapy. The financing supported electroCore's mission to advance neuromodulation without surgery, positioning it as a leader in bioelectronic medicine for conditions like cluster headaches. Investors expressed confidence in the platform's potential to impact healthcare cost-effectively.
Jun-14Series ACore Ventures; Easton Capital; Merck Global Health Innovation Fund$55M—electroCore, a New Jersey-based electroceutical company, developed non-invasive vagus nerve stimulation (nVNS) therapy using its gammaCore device for treating conditions in neurology, psychiatry, gastroenterology, primary headache, bronchoconstriction, epilepsy, gastric motility disorders, depression, and anxiety. The therapy targets over-expression of the excitatory neurotransmitter glutamate, offering a cost-effective alternative to invasive VNS at around $30,000. In Europe, gammaCore received CE marks for several indications, while in the US, pivotal trials for headache were concluding around mid-2014. Around June 30, 2014, electroCore's funding initiative, initially announced as $40 million in April 2013, was oversubscribed by $10 million, bringing the total to $50 million. Investors included Merck’s Global Health Innovation Fund (GHI Fund), Easton Capital, and Core Ventures, with the final tranche increased from an optional $15 million. Later, electroCore completed a $70 million Series B funding round, led by Core Ventures II with participation from Merck GHI Fund (a Series A investor), Gakasa (affiliate of Knoll Capital), American Investment Holdings LLC, and Vinik Family Foundation. Proceeds funded commercial launch and expansion of gammaCore therapy. Core Ventures and Merck GHI showed ongoing support, highlighting confidence in electroCore's nVNS platform in the emerging neuromodulation market previously limited by surgical delivery.

electroCore M&A Activity

electroCore has acquired 1 company to date.

Last acquisition by electroCore was on December 17th 2024. electroCore acquired NeuroMetrix for $9M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by electroCore

NeuroMetrix
Description
NeuroMetrix is a Woburn-headquartered medical technology company that develops wearable neurostimulation therapies and point-of-care diagnostic tests for chronic pain and peripheral neuropathies. Its Quell device delivers transcutaneous electrical nerve stimulation for pain relief from conditions like diabetic neuropathy and fibromyalgia. The ADVANCE NCS/EMG system performs in-office nerve conduction studies to diagnose diabetic peripheral neuropathy and carpal tunnel syndrome. Founded in 1996, NeuroMetrix holds FDA clearances for its products and trades publicly on Nasdaq under the ticker NURO. The company serves healthcare providers through sales representatives and direct-to-consumer channels via its online platform.
HQ CountryUnited States
HQ City
Boston, MA
Deal Date17 Dec 2024
Valuation$9M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all electroCore acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About electroCore

When was electroCore founded?electroCore was founded in 2005.
Where is electroCore headquartered?electroCore is headquartered in United States.
How many employees does electroCore have?As of today, electroCore has over 73 employees.
Who is the CEO of electroCore?electroCore's CEO is Daniel S. Goldberger.
Is electroCore publicly listed?Yes, electroCore is a public company listed on Nasdaq.
What is the stock symbol of electroCore?electroCore trades under ECOR ticker.
When did electroCore go public?electroCore went public in 2018.
Who are competitors of electroCore?electroCore main competitors include Sequana Medical, Svas Biosana, Envoy Medical, Anatolia Geneworks, Sensus Healthcare, Modulight, K Pharma, Cleo Diagnostics, Bactiguard, Baird Medical Investment.
What is the current market cap of electroCore?electroCore's current market cap is $55M.
What is the current revenue of electroCore?electroCore's last 12 months revenue is $36M.
What is the current revenue growth of electroCore?electroCore revenue growth (NTM/LTM) is 30%.
What is the current EV/Revenue multiple of electroCore?Current revenue multiple of electroCore is 1.6x.
Is electroCore profitable?No, electroCore is not profitable.
What is the current EBITDA of electroCore?electroCore has negative EBITDA and is not profitable.
What is electroCore's EBITDA margin?electroCore's last 12 months EBITDA margin is (21%).
What is the current EV/EBITDA multiple of electroCore?Current EBITDA multiple of electroCore is (7.4x).
How many companies electroCore has acquired to date?As of May 2026, electroCore has acquired 1 company.
What was the largest acquisition by electroCore?$9M acquisition of NeuroMetrix on 17th December 2024 was the largest M&A electroCore has done to date.
What companies electroCore acquired?electroCore acquired NeuroMetrix.
In how many companies electroCore has invested to date?electroCore hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to electroCore

Lists including electroCore

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial